BTK and B-cell chronic lymphocytic leukemia: Orelabrutinib, a BTK inhibitor developed by InnoCare Pharma, was approved by the National Medical Products Administration (NMPA) in December 2020 for treating mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic leukemia (SLL).